FDA Okays Cancer Drugs Faster Than EMA. But at What Cost?

The FDA approves new cancer drugs much sooner than its European counterpart, but is faster better? Experts discuss the pros and cons of this speedy review process.
Medscape Medical News

Leave a Reply

Your email address will not be published. Required fields are marked *